Abstract: A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.

Abstract: A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.

Abstract: The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A and/or B in the presence of a microbial substance which is capable of deacylating WF14573A and/or B. Also provided are an antimicrobial agent comprising WF14573 and carrier(s), a pharmaceutical composition comprising an effective amount of WF14573 and pharmaceutically acceptable carrier(s), a method for killing microorganisms by applying WF14573 to the microorganisms, and use of WF14573 for the treatment of infectious diseases caused by pathogenic microorganisms.

Abstract: A cyclic tetrapeptide compound and use thereof.

Abstract: The present invention provides a new bioactive compound of formula (I), which has an antimicrobial activity against pathogenic microorganisms, and a process for production thereof. Also provided are a pharmaceutical composition comprising the compound and pharmaceutically acceptable carrier, a use of the WF002 as a medicament and use of the compound for manufacture of the medicament for treatment of infectious disease.

Abstract: A process for producing a compound of the general formula (I): (wherein R1 represents hydrogen, a lower alkanoyl group or a lower alkyl group; R2 and R3 each represents hydrogen or a lower alkanoyl group) characterized in that a compound of the general formula (II): (wherein R1, R2 and R3 are respectively as defined above) is reacted with a culture of a strain of microorganism belonging to the genus Fusarium or its cells harvested by filtering the broth.

Abstract: The invention relates to new polypeptide compounds represented by the following formula [I]: wherein R1 is hydrogen, etc, R2 is hydrogen, etc, R3 is hydrogen, etc, and R4 is hydrogen, etc, or a salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

Abstract: A process for producing a compound of the general formula (I): (wherein R1 represents hydrogen, a lower alkanoyl group or a lower alkyl group; R2 and R3each represents hydrogen or a lower alkanoyl group) characterized in that a compound of the general formula (II): (wherein R1, R2 and R3 are respectively as defined above) is reacted with a culture of a strain of microorganism belonging to the genus Fusarium or its cells harvested by filtering the broth.

Abstract: The present invention relates to a novel fatty acid derivative of the following formula: ##STR1## wherein R.sup.1 is acyl group, etc.;R.sup.2 is acyl(lower)alkyl;R.sup.3 is lower alkyl, etc.;R.sup.4 is hydrogen, etc.; andX is --O--, etc;and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said fatty acid derivative or a salt thereof; a pharmaceutical composition comprising said fatty acid derivative or a pharmaceutically acceptable salt thereof; etc.

Abstract: 1. WF16616 substance represented by the following structural formula (1) or its pharmaceutically acceptable salt. ##STR1## WF16616 substance exhibits an antimicrobial activity, especially an excellent antifungal activity.

Abstract: A compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or hydroxy, R.sup.2 is hydrogen or hydroxy, R.sup.3 is hydroxy or hydroxysulfonyloxy, with proviso that when R.sup.1 is hydrogen, R.sup.2 is hydrogen, or a phamaceutically acceptable salt thereof. The compound can be used in a method for treating infectious diseases caused by pathogenic microorganism.

Abstract: The invention relates to a method of producing cyclosporin A and/or C which is characterized by culturing a cyclosporin A and/or C-producing strain of microorganism belonging to the genus Nectria (e.g. Nectria sp. F-4908) and recovering cyclosporin A and/or C from the resulting cultured broth.

Abstract: A polypeptide compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or acyl group, R.sup.2 is hydroxy or acyloxy,R.sup.3 is hydroxysulfonyloxy, andR.sup.4 is hydrogen or carbamoyl,with proviso thatR.sup.1 is not palmitoyl, when R.sup.2 is hydroxy,R.sup.3 is hydroxysulfonyloxy andR.sup.4 is carbamoyl,and a pharmaceutically acceptable salt thereof.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each lower alkyl, R.sup.4 is hydrogen or hydroxy, and a heavy solid line means a double bond when R.sup.4 is hydrogen and a single bond when R.sup.4 is hydroxy is useful in the treatment of diseases caused by reactive oxygen species and organic radicals.

Abstract: This invention relates to new compounds WF 2015 A and B which have immunosuppressing activity and antitumor activity, to a process for producing WF 2015 A and B by culturing a WF 2015 A and/or B-producing strain belonging to the genus Scolecobasidium in a nutrient medium, and to a pharmaceutical composition comprising the same.

Abstract: Novel compounds of the following formula have restorative pharmacological activities in immuno-deficient hosts, ##STR1## wherein R.sup.1 is amino or a protected amino group,R.sup.2 is hydrogen, carboxy or a protected carboxy group,R.sup.3 is hydrogen, carboxy or a protected carboxy group,R.sup.4 is lower alkyl, amino(lower)alkyl, protected amino(lower)alkyl, carbamoyl(lower)alkyl or protected carbamoyl(lower)alkyl,R.sup.5 is hydrogen or lower alkyl, andR.sup.6 is hydrogen, hydroxyphenyl(lower)alkyl, imidazolyl(lower)alkyl or indolyl(lower)alkyl.

Abstract: The invention relates to a new compound, designated FR-68504. The compound has antitimor activities and is effective in the treatment of various tumors in both human beings and animals.There is also provided a process for preparing FR-68504 compound which comprises culturing a FR-68504 producing strain belonging to the genus Amauroascus in a nutrient medium.Pharmaceutical composition comprising FR-68504 as an active ingredient is also described.

Abstract: A pharmaceutical composition comprising an amount of a polypeptide of the formula: ##STR1## wherein R.sup.1 is hydrogen or an acyl group, R.sup.2 is hydroxy or an acyloxy group, R.sup.3 is hydrogen, hydroxy or hydroxysulfonyloxy, R.sup.4 is hydrogen or carbamoyl, and R.sup.5 and R.sup.6 are each hydrogen or hydroxy, with the proviso that (i) R.sup.2 is acyloxy when R.sup.3 is hydrogen, and (ii) R.sup.5 is hydrogen when R.sup.6 is hydrogen, or a pharmaceutically acceptable salt thereof, is useful in the prevention or treatment of Pneumocystis carinii infection.